Research programme: cancer therapeutics - Adamis Pharmaceuticals Corporation

Drug Profile

Research programme: cancer therapeutics - Adamis Pharmaceuticals Corporation

Alternative Names: APC-200; APC-300; CPC-200; CPC-300; Prost-aid; Prost-guard; Prost-vance

Latest Information Update: 09 Jan 2014

Price : $50

At a glance

  • Originator Wisconsin Alumni Research Foundation
  • Developer Adamis Pharmaceuticals Corporation
  • Class Small molecules
  • Mechanism of Action Apoptosis stimulants; Oxidoreductase inhibitors; Signal transduction pathway inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Pancreatic cancer; Prostate cancer

Most Recent Events

  • 31 Jul 2013 APC 200 is still undergoing preclinical development in USA
  • 31 Jul 2013 Discontinued - Preclinical for Prostate cancer in USA (Implant)
  • 21 Jul 2011 Pharmacodynamics data from a preclinical study in Prostate cancer released by Adamis
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top